| レジメン分類 |
レジメン名 |
| 頭頸部癌[Ｃ03] |
FP |
| 3wCDDP-RT |
| 5-FU局所動注 |
| DTX |
| PTX |
| FP+Cmab |
| Cmab |
| Cmab+RT |
| PTX+Cmab |
| Cmab+5-FU+CBDCA |
| nivolumab（2週間） |
| pembrolizumab＋FP |
| pembrolizumab+CBDCA＋5-FU |
| pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| nivolumab(4週間) |
| weekyCDDP-RT |
| weekyCBDCA-RT |
| 食道癌[Ｃ15] |
FP |
| 3wDTX |
| NDP+5-FU |
| NDP+5-FU+RT |
| 5-FU |
| DTX+NDP+RT |
| wPTX |
| nivolumab(2週間) |
| nivolumab(4週間) |
| pembrolizumab＋FP |
| pembrolizumab＋5-FU |
| DCF |
| FP（1000+75）-RT |
| FP（700+70）-RT |
| nivolumab+ipilimumab |
| nivolumab+FP |
| pembrolizumab(維持療法) |
| 胃癌[Ｃ16] |
S-1+CDDP |
| wPTX |
| 3wDTX |
| CPT-11(A法) |
| CPT-11(B法) |
| 5-FU |
| Cape＋CDDP |
| trastuzumab+Cape＋CDDP |
| trastuzumab+Cape |
| trastuzumab+5-FU＋CDDP |
| trastuzumab+S-1+CDDP |
| CapeOX |
| SOX |
| ramucirumab |
| ramucirumab+PTX |
| 5-FU＋CDDP |
| mFOLFOX6 |
| mFOLFOX6-IF |
| nivolumab（2週間） |
| weekly nab-PTX |
| 3wDTX＋S-1 |
| ramucirumab+nab-PTX |
| trastuzumab＋CapeOX |
| nivolumab(4週間) |
| trastuzumab deruxtecan |
| trastuzumab+SOX |
| nivolumab+SOX |
| zolbetuximab＋cape |
| zolbetuximab＋CAPOX |
| zolbetuximab＋mFOLFOX6 |
| zolbetuximab＋mFOLFOX6-IF |
| zolbetuximab + sLV5-FU2 |
| zolbetuximab + sLV5-FU2-IF |
| pembrolizumab+CAPOX |
| pembrolizumab+Cape |
| pembrolizumab(維持療法) |
| nivolumab+mFOLFOX6 |
| nivolumab+mFOLFOX6-IF |
| nivolumab+sLv+5-FU2 |
| nivolumab+sLv+5-FU2-IF |
| pembrolizumab+trastuzumab(3週毎)+CAPOX |
| pembrolizumab+trastuzumab(3週毎)+Cape |
| pembrolizumab+trastuzumab(3週毎) |
| 大腸癌[Ｃ18] |
FOLFIRI |
| BV+FOLFIRI |
| FOLFIRI-IF |
| BV+FOLFIRI-IF |
| mFOLFOX6 |
| BV+mFOLFOX6 |
| mFOLFOX6-IF |
| BV+mFOLFOX6-IF |
| sLV5-FU2 |
| BV+sLV5-FU2 |
| Cmab+CPT-11 |
| Cmab |
| CapeOX |
| BV+CapeOX |
| CPT-11(B法) |
| Pmab+mFOLFOX6 |
| Pmab |
| Pmab+FOLFIRI |
| Pmab+FOLFIRI-IF |
| BV+sLV5-FU2-IF |
| sLV5-FU2-IF |
| 2wCmab+mFOLFOX6 |
| 2wCmab+FOLFIRI |
| 2wCmab+mFOLFOX6-IF |
| 2wCmab+FOLFIRI-IF |
| WHF(weekly high-dose 5-FU) |
| CPT-11(A法) |
| 5-FU(RPMI) |
| BV+(S-1 or Cape) |
| FOLFOXIRI |
| BV+SOX |
| IRIS |
| Pmab+CPT-11 |
| FOLFOXIRI-IF |
| BV+FOLFOXIRI |
| BV+FOLFOXIRI-IF |
| ramucirumab＋FOLFIRI |
| ramucirumab＋FOLFIRI-IF |
| BV+IRIS |
| SOX |
| Pmab+mFOLFOX6-IF |
| 2wCmab+sLV5-FU2 |
| 2wCmab+sLV5-FU2-IF |
| BV+CAPIRI |
| CAPIRI |
| Cmab+encorafenib |
| Cmab+encorafenib+binimetinib |
| BV + 4week ロンサーフ |
| pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| pertuzumab+trastuzumab(3週毎) |
| 2wCmab |
| Pmab+sLV5-FU2 |
| Pmab+sLV5-FU2-IF |
| フェスゴ配合皮下注 |
| BV＋2weekロンサーフ |
| nivolumab+ipilimumab |
| nivolumab(2週間) |
| nivolumab(4週間) |
| 肛門癌[Ｃ21] |
5-FU+MMC+RT |
| 肝・胆管癌[Ｃ22] |
S-1+GEM |
| GEM |
| TACE(シスプラチン肝動注用) |
| CDDP+GEM |
| 肝動注 weekly FP |
| TACE(EPI) |
| atezolizumab+BV |
| GCS |
| durvalumab＋GC |
| durvalumab(胆道癌維持療法) |
| tremelimumab+durvalumab |
| durvalumab(肝細胞癌) |
| pembrolizumab + GC |
| pembrolizumab + GEM |
| 膵癌[Ｃ25] |
（進行再発）S-1+GEM |
| （術前） S-1+GEM |
| GEM |
| FOLFIRINOX |
| GEM+erlotinib |
| nab-PTX+GEM |
| FOLFIRINOX-IF |
| modified FOLFIRINOX |
| オニバイド＋l-LV＋5-FU |
| modified FOLFIRINOX-IF |
| オニバイド＋l-LV＋5-FU-IF |
| 膵・消化管神経内分泌腫瘍[Ｃ26] |
WeeklySTZ |
| 小細胞肺癌[Ｃ34] |
CDDP+CPT-11 |
| CDDP+VP-16+RT |
| CDDP+VP-16 |
| AMR |
| CBDCA+VP-16 |
| CBDCA+CPT-11 |
| NGT |
| atezolizumab+CBDCA+VP-16 |
| atezolizumab |
| durvalumab+CDDP+VP-16 |
| durvalumab+CBDCA+VP-16 |
| durvalumab（維持療法） |
| 非小細胞肺癌[Ｃ35] |
CDDP+CPT-11 |
| CDDP+VNR |
| CDDP+DTX |
| CBDCA+PTX |
| CDDP+GEM |
| PEM |
| 3wDTX |
| VNR |
| GEM |
| CDDP+VNR+RT |
| CDDP+PEM |
| CBDCA+GEM |
| PEM+CBDCA |
| CBDCA+wPTX |
| S-1+CDDP+RT |
| CPT-11+S-1 |
| weekly nab-PTX |
| S-1+CBDCA |
| PEM+CBDCA+BV |
| PTX+CBDCA+BV |
| CBDCA+nab-PTX |
| DTX+NDP |
| BV |
| PEM+BV |
| CDDP+DTX+RT |
| nivolumab（2週間） |
| wPTX+wCBDCA+RT |
| pembrolizumab(3週間） |
| atezolizumab |
| pembrolizumab+PEM+CBDCA |
| pembrolizumab+PEM |
| pembrolizumab+CBDCA+nab-PTX |
| pembrolizumab+CBDCA+PTX |
| durvalumab |
| atezolizumab＋BV＋PTX＋CBDCA |
| atezolizumab＋BV |
| ramucirumab+DTX |
| atezolizumab+PEM+CBDCA |
| atezolizumab+PEM |
| atezolizumab+CBDCA+nab-PTX |
| CDDP+PEM+BV |
| pembrolizumab(6週間) |
| nivolumab（4週間） |
| nivolumab+ipilimumab |
| nivolumab+ipilimumab+PTX+CBDCA |
| nivolumab+ipilimumab+PEM+CBDCA |
| PEM+CBDCA+gefitinib |
| PEM+gefitinib |
| ramucirumab+erlotinib |
| necitumumab+CDDP+GEM |
| necitumumab |
| trastuzumab deruxtecan |
| nivolumab+PEM+CBDCA（術前） |
| nivolumab+PTX+CBDCA（術前） |
| PEM+CBDCA+osimertinib |
| PEM+osimertinib |
| 悪性黒色腫[Ｃ43] |
DTIC |
| nivolumab（2週間） |
| ipilimumab |
| nivolumab（4週間） |
| nivolumab＋ipilimumab |
| 悪性胸膜中皮腫[Ｃ45] |
nivolumab + ipilimumab |
| pembrolizumab+PEM+CBDCA |
| pembrolizumab維持療法（3週間) |
| pembrolizumab維持療法（6週間) |
| 肉腫[Ｃ49] |
IFM |
| DXR |
| IFM+DXR |
| GEM+DTX |
| IFM+PTX |
| IFM+CDDP |
| trabectedin |
| High-dose IFM |
| eribulin |
| VDC (VDC-IE交替療法) |
| IE (VDC-IE交替療法) |
| VAC (VDC-IE交替療法) |
| 乳癌[Ｃ50] |
wPTX |
| wPTX+trastuzumab(毎週) |
| 3wDTX |
| VNR+trastuzumab(毎週) |
| trastuzumab(毎週) |
| trastuzumab(3週毎) |
| 3wDTX+trastuzumab(3週毎) |
| VNR |
| CMF |
| TC |
| GEM |
| nab-PTX |
| AC |
| eribulin |
| PTX+BV |
| weekly nab-PTX |
| weekly nab-PTX+trastuzumab(毎週) |
| eribulin+trastuzumab(毎週) |
| pertuzumab+trastuzumab(3週毎)+DTX |
| pertuzumab+trastuzumab(3週毎)+wPTX |
| T-DM1 |
| pertuzumab+trastuzumab(3週毎)+eribulin |
| pertuzumab+trastuzumab(3週毎) |
| nab-PTX+trastuzumab(3週毎) |
| atezolizumab+nab-PTX |
| trastuzumab deruxtecan |
| pembrolizumab+GEM+CBDCA |
| pembrolizumab+wPTX |
| pembrolizumab+wPTX+wCBDCA |
| pembrolizumab+AC |
| pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| pembrolizumab+nab-PTX |
| フェスゴ配合皮下注 |
| フェスゴ＋3ｗDTX |
| フェスゴ＋wPTX |
| ddAC |
| sacituzumab govitecan |
| datopotamab deruxtecan |
| 子宮頚癌[Ｃ53] |
CDDP+RT |
| PTX+CDDP |
| NDP+RT |
| CPT-11+NDP |
| TC |
| TC+BV |
| TP（PTX3時間） |
| TP（PTX3時間）+BV |
| cemiplimab |
| pembrolizumab+TC |
| pembrolizumab+TC+BV |
| pembrolizumab+TP（PTX3時間） |
| pembrolizumab+TP（PTX3時間）＋BV |
| pembrolizumab+BV |
| pembrolizumab |
| BV |
| pembrolizumab+CDDP+RT |
| tisotumab vedotin |
| 子宮体癌[Ｃ54] |
DXR+CDDP |
| DTX |
| TC |
| pembrolizumab(3週間)+lenvatinib |
| pembrolizumab(6週間)+lenvatinib |
| durvalumab+TC |
| durvalumab+olaparib |
| durvalumab |
| pembrolizumab+TC |
| pembrolizumab維持（6週間) |
| durvalumab+DC |
| 卵巣癌[Ｃ56] |
CPT-11+CDDP |
| dd-TC |
| PLD |
| TC |
| DC |
| NDP |
| GEM |
| CPT-11(A法) |
| CBDCA |
| TC+BV |
| DP+BV |
| BV |
| CBDCA+GEM+BV |
| CBDCA+GEM |
| DC+BV |
| PLD+BV |
| NGT |
| wPTX+BV |
| wPTX |
| 3wPTX |
| BV＋olaparib |
| weeklyTC |
| CPT-11（B法） |
| PLD+CBDCA+BV |
| PLD+CBDCA |
| 3wPTX+BV |
| 絨毛性疾患[Ｃ57] |
EMA-CO |
| MTX単独療法 |
| MTX-Folinic acid療法 |
| 前立腺癌[Ｃ61] |
3wDTX |
| CTX |
| CDDP |
| ３wDOC+ADT+ダロルタミド |
| 胚細胞腫瘍[Ｃ62] |
BEP |
| EP |
| 精巣腫瘍[Ｃ63] |
CBDCA |
| 腎細胞癌[Ｃ64] |
temsirolimus |
| nivolumab(2週間) |
| nivolumab+ipilimumab |
| pembrolizumab(3週間)+axitinib |
| pembrolizumab(6週間)+axitinib |
| nivolumab（4週間） |
| pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| pembrolizumab(3週間)+lenvatinib |
| pembrolizumab(6週間)+lenvatinib |
| avelumab+axitinib |
| 上部尿路癌[Ｃ65・Ｃ67] |
GC |
| GEM+CBDCA |
| pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| enfortumab vedotin |
| avelumab |
| nivolumab(2週間) |
| nivolumab(4週間) |
| wPTX |
| pembrolizumab(3週間)+enfortumab vedotin |
| dose-denseMVAC |
| 原発不明がん[Ｃ76] |
TC |
| nivolumab(2週間) |
| nivolumab(4週間) |
| 脳腫瘍[Ｃ71] |
BV（2週毎） |
| BV（3週毎） |
| 神経内分泌癌[Ｃ80] |
CDDP+VP-16 |
| CBDCA＋VP-16 |
| AMR |
| NGT |
| 悪性リンパ腫[Ｃ85] |
ABVD |
| CHOP |
| R-CHOP |
| CHASE |
| R-CHASE |
| THP-COP |
| R-THP-COP |
| COP |
| R-COP |
| rituximab |
| R-CHOP(1日法) |
| bendamustine単剤 |
| bendamustine-R |
| ABVd |
| High-doseMTX+Ara-C |
| GEM |
| R-miniCHOP |
| R-CEOP |
| GDP |
| miniCHOP |
| High-dose MTX |
| R-GDP |
| R-GCD |
| adcetris |
| nivolumab(2週間) |
| adcetris＋AVD |
| DeVIC |
| GCD |
| VR-CAP |
| DA-R-EPOCH |
| nivolumab(4週間) |
| G-Bendamustine |
| Gazyva維持療法 |
| R-CEOP(1日法） |
| R-miniCHOP(1日法） |
| polatuzumab+bendamustine-R |
| R-CHASE(1日法) |
| R-MPV |
| Pola-R-CHP |
| R2 |
| RT-2/3DeVIC |
| R-COP(1日法) |
| adcetris + CHP |
| 多発性骨髄腫[Ｃ90] |
BD |
| BDweekly |
| MPB(VMP) |
| BD(皮下注) |
| BDweekly(皮下注) |
| MPB(VMP)(皮下注) |
| BCD(CyBorD)(皮下注) |
| BLd(RVD)(皮下注) |
| PBd(PVd)(皮下注) |
| DLd療法(皮下注） |
| RVD-lite(皮下注) |
| DKd(皮下注)(75歳以下) |
| DKd(皮下注)(76歳以上) |
| DPd(皮下注)(75歳未満) |
| DPd(皮下注）(75歳以上) |
| DBd(皮下注) |
| IsaPd |
| wKd |
| KRd |
| Isa20+d |
| EPd |
| 白血病[Ｃ91] |
DNR+Ara-C |
| IDR+Ara-C |
| ATRA+IDR+Ara-C |
| azacitidine（皮下投与）+ベネトクラクス |
| azacitidine（点滴静注）+ベネトクラクス |
| Low-dose AraC(皮下投与)+ベネトクラクス |
| MSI-HighまたはTMB-Highを有する固形癌[Ｃ98] |
pembrolizumab(3週間) |
| pembrolizumab(6週間) |
| その他[Ｃ99] |
MCNU |
| MTX髄腔内投与 |
| infliximab(関節リウマチ) |
| infliximab(関節リウマチ、乾癬以外) |
| azacitidine(皮下投与) |
| azacitidine |
| CPAパルス(間質性肺炎) |
| CPAパルス(ﾘｳﾏﾁ性疾患) |
| abatacept |
| tocilizumab |
| rituximab |
| rituximab(天疱瘡) |
| 中等量Ara-C |
| rituximab(難治性のネフローゼ症候群) |
